AbbVie stock trades near 52-week high as Q2 2026 immunology growth lifts earnings
Published on 08/26/2026 at 20:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock is hovering close to a fresh 52-week high in late August 2026, supported by double-digit revenue growth and stronger earnings from its latest reported quarter. Per late August 2026 market data, shares trade in the mid-$260s and are up in the mid-teens percent year-to-date, underscoring how investors have rewarded the company’s progress in offsetting the Humira patent cliff.
According to a recent market overview, AbbVie shares changed hands at $265.56 as of August 25, 2026, placing the stock only slightly below a 52-week high of $267.47. One analysis notes that the stock has climbed from about $249 to roughly $264 since mid-August 2026, a gain of 6%, and that it has delivered a 16% advance so far in 2026.
Q2 2026 results boost confidence
Fresh Q2 2026 numbers give investors a clearer picture of why AbbVie stock has been resilient. In the second quarter of 2026, the company reported revenue of $16.99 billion, representing an increase of 10.2% compared with the same quarter a year earlier. The company’s adjusted earnings per share for Q2 2026 came in at $3.65, up from $2.97 in the prior-year period, a jump of 22.9% that reflects both top-line growth and operating leverage.
Market commentary highlights that this Q2 2026 performance also exceeded consensus expectations. Analysts had expected adjusted EPS of $3.61 for the quarter, so the reported $3.65 result beat forecasts by $0.04 per share. Revenue of $16.99 billion also came in ahead of an average estimate of $16.80 billion, and this outperformance has been a key factor in the stock trading close to its 52-week high.
Immunology engines Skyrizi and Rinvoq
One of the most closely watched elements of AbbVie’s story is the transition away from heavy dependence on Humira. The latest quarter shows that the newer immunology therapies Skyrizi and Rinvoq have become central growth pillars. In Q2 2026, combined revenue from Skyrizi and Rinvoq exceeded $8 billion. Skyrizi contributed $5.51 billion in sales, an increase of 24.4% year-over-year, while Rinvoq generated $2.53 billion, registering growth of 24.5% versus the prior-year quarter.
This double-digit expansion in the immunology franchise helps explain why total company revenue rose 10.2% and why adjusted EPS grew 22.9% in Q2 2026. The strong performance of Skyrizi and Rinvoq indicates that AbbVie’s strategy to build a diversified portfolio of high-growth therapies is gaining traction, and it reduces the risk that the loss of Humira exclusivity could significantly undermine overall group earnings.
Guidance and full-year 2026 outlook
In conjunction with the Q2 2026 report, AbbVie also laid out guidance for the coming quarters. For Q3 2026, the company is guiding to adjusted EPS in the range of $3.84 to $3.88, signaling that management expects earnings to continue climbing from the Q2 base of $3.65. That outlook implies another solid quarter of profit growth if the company delivers within that range.
For the full year 2026, AbbVie has communicated an adjusted EPS goal of $14.06, accompanied by an updated range between $13.87 and $14.07. Relative to the Q2 2026 run-rate, this guidance suggests that the company anticipates maintaining robust profitability over the second half of the year. Data compiled from analyst estimates also indicate that the Street on average forecasts adjusted EPS of 14.06 for 2026, in line with the company’s outlook.
Dividend policy and yield support
AbbVie continues to emphasize shareholder returns through dividends. For 2026, the company has indicated a quarterly dividend of $1.73 per share, which equates to $6.92 per share on an annualized basis. Using a share price level around the mid-$240s referenced in recent commentary, this dividend represents a yield of 2.77%, offering income-focused investors a meaningful cash return in addition to any potential capital appreciation.
Recent notes on the stock also highlight that this dividend profile supports AbbVie’s perception as a dependable income name. At the same time, the combination of a mid-single-digit dividend yield and double-digit earnings growth leads many observers to see the stock as a blend of income and growth, particularly now that newer therapies are driving a larger share of revenue.
Valuation and analyst sentiment
Analyst sentiment remains constructive. Market data indicate that AbbVie shares carry an average rating of Moderate Buy, reflecting a generally positive stance among sell-side firms. The same data set reports an average price target of $275.95, which sits slightly above the recent trading level of around $265 to $266. This implies a modest upside from current prices if the company delivers on its earnings and revenue guidance.
The quantified gap between the recent share price of $265.56 and the average target of $275.95 is just over $10 per share, suggesting that analysts see additional room for appreciation but not a dramatic re-rating. For investors, this means the market has already priced in a significant portion of AbbVie’s success in transitioning its portfolio, though there is still expectation for incremental gains as the pipeline and new launches contribute more materially.
Institutional flows and market positioning
Recent filings show that institutional investors continue to adjust their exposure to AbbVie. One example notes that a major hedge fund manager increased their stake in the company significantly in Q2 2026, and since that filing on August 14, 2026, AbbVie stock has advanced from about $249 per share to roughly $264 per share, delivering a 6% gain in a short span.
Other institutional reports describe new positions and partial disposals among asset managers, but the broader picture is that AbbVie remains widely held and closely followed. The combination of a large market capitalization, a sizable dividend, and a pipeline of high-profile therapies makes the stock a core holding in many diversified healthcare and dividend portfolios.
Balance sheet metrics and profitability
The latest quarterly report also sheds light on AbbVie’s profitability metrics. For Q2 2026, commentary notes that the company delivered a net margin of 9.80% and a negative return on equity of 422.07%. The negative reported return on equity primarily reflects accounting and capital structure effects rather than an underlying deterioration in operating performance, given that revenue and adjusted EPS both increased during the period.
Revenue growth of 10.2% in Q2 2026, while adjusted EPS rose 22.9%, indicates that AbbVie is widening its profit per share faster than its top line. This pattern suggests improving operational efficiency, as higher-margin products like Skyrizi and Rinvoq contribute a growing share of revenue, and as the company continues to manage costs and leverage its existing infrastructure.
Product spotlight: Skyrizi in immunology
Skyrizi, one of AbbVie’s flagship immunology products, has become a central focus for the company’s growth strategy. In Q2 2026, Skyrizi generated $5.51 billion in revenue, reflecting 24.4% year-over-year growth. This performance underscores the drug’s strong adoption across its approved indications, which include chronic inflammatory diseases where long-term treatment regimens are common.
The robust trajectory of Skyrizi, alongside Rinvoq, reinforces AbbVie’s repositioning as a diversified immunology leader beyond Humira. With combined Skyrizi and Rinvoq sales surpassing $8 billion in Q2 2026 and growing in the mid-20 percent range, these therapies are now critical pillars supporting the company’s revenue base and underpinning management’s confidence in its full-year 2026 guidance.
AbbVie stock price context
From a trading perspective, AbbVie stock’s proximity to its 52-week high is a key technical reference point for investors. The share price of $265.56 as of August 25, 2026, stands just below the 52-week peak of $267.47, indicating that the market is valuing the company near the upper end of its recent range. The stock’s year-to-date gain of 16% further signals that the market has responded favorably to the company’s execution in 2026.
With the stock only a few dollars shy of its 52-week high and an average analyst target of $275.95, investors are watching whether upcoming quarters, including the guided Q3 2026 adjusted EPS range of $3.84 to $3.88, will be strong enough to justify further upside. At current levels, the balance between valuation, dividend income, and earnings momentum is central to how market participants assess the risk-reward profile of AbbVie stock.
Fact box
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Price (as of August 25, 2026, 4:00 p.m. ET): $265.56 USD
Market cap: not specified in current sources
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
